Maciej Banach on Muck Rack

Maciej Banach

Łódź
As seen in: Color Research & Application, Nature, Wiley Online Library, Cambridge University Press & Assessment, Memory Studies, BMJ Open, Educational Studies, Frontiers, MDPI, SAGE Publishing and
Prof. Cardiology at @umedlodz & @LiverpoolCCS; @ExpertLipid and LBPMC President; European Program for Prevention Lead; @ArchMedSci Editor & #EHJOpen Co-Editor
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Maciej

Contact Maciej, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial

|
By Stephen Nicholls Verified, Adam Nelson, Marc Ditmarsch, John J. P. Kastelein, Christie M. Ballantyne, Kausik K. Ray, Ann Marie Navar, Steven Nissen, Anne C. Goldberg, Liam R. Brunham, Erin Wuerdeman, Annie Neild, Douglas Kling, Andrew Hsieh, Julie Butters, Brian A. Ference, Ulrich Laufs, Maciej Banach, Roxana Mehran, Alberico L Catapano, Michael Szarek, Violeta Balinskaite, Michael Davidson
| Nature Verified
Correction to: Nature Medicine https://doi.org/10.1038/s41591-025-04179-4, published online 27 February 2026.
Open in Who Shared Issue with article?

Editorial: New drugs in lipid lowering therapy

|
By Maciej Banach
| Frontiers
Cardiovascular disease (CVD) remains one of the largest global health challenges, and despite decades of progress in prevention, low-density lipoprotein cholesterol (LDL-C) continues to be a key driver of risk (). Statins have long been the cornerstone of treatment, but many patients, especially those at very high risk or who cannot tolerate statins. Need additional options (, ). That need has brought us in a new era of lipid-lowering therapies (LLTs), which is the focus of this Research Topic.
Open in Who Shared Issue with article?

Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial - Nature Medicine

|
By Stephen Nicholls Verified, Adam Nelson, Marc Ditmarsch, Christie M. Ballantyne, Kausik K. Ray, Ann Marie Navar, Steven Nissen, Anne C. Goldberg, Liam R. Brunham, Annie Neild, Douglas Kling, Andrew Hsieh, Julie Butters, Brian A. Ference, Ulrich Laufs, Maciej Banach, Roxana Mehran, Alberico L Catapano, Michael Szarek, Violeta Balinskaite, Michael Davidson, John J. P. Kastelein, Erin Wuerdeman
| Nature Verified
Abstract Most patients with heterozygous familial hypercholesterolemia fail to achieve adequate low-density lipoprotein (LDL) cholesterol lowering. Here we carried out a randomized trial to test the safety and efficacy of obicetrapib, a highly selective cholesteryl ester transfer protein inhibitor that lowers LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia and an LDL cholesterol level ≥70 mg dl−1 on maximally tolerated lipid-lowering therapy.
Open in Who Shared Issue with article?
See all 120 licensed articles (130 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified